In consultation: Guidance and quality standards
Showing 1 to 10 of 16
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver | Interventional procedure consultation | HealthTech guidance | |
| Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment | Draft guidance | HealthTech guidance | |
| Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Topical tapinarof for treating mild to severe plaque psoriasis ID6712 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment | Draft guidance | HealthTech guidance | |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529] | Draft guidance | Technology appraisal guidance | |
| Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Semaglutide 7.2 mg dose for managing obesity ID6699 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |